510(k) device
Marigen Wound Extra
Kerecis Limited · Wound Dressing With Animal-Derived Material(S) (KGN, Unclassified) · First FDA decision Oct 23, 2013, newest Jul 16, 2025BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
3
Naming "Marigen"
MAUDE reports
0
Brand "Marigen", since 2015
PubMed studies
4
Mentioning "Marigen"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Marigen Wound Extra
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K251845 · Decided Jul 16, 2025 · 30 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
- MariGen Wound Extra510(k)
K190528 · Decided Jul 10, 2019 · 128 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
- MARIGEN WOUND DRESSING510(k)
K132343 · Decided Oct 23, 2013 · 85 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Marigen", any status and sponsor, newest update first.
- Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority StudyCompleted
Kerecis Ltd.Not on our public-company list
NCT01917591 · 81 participants · Start Jan 2013 · Primary completion Jun 2013
Device: Punch biopsies treated with MariGen Wound ECM dressing; Punch biopsies treated with Oasis ECM dressing · For: Punch Biopsy Wounds; Healing Times
Sites: Reykjavik, Iceland
Kerecis Ltd.Not on our public-company list
NCT03984331 · 5 participants · Start Feb 14, 2019 · Primary completion Jun 8, 2021
Device: Fish skin; Cadaver skin · For: Burns
Sites: Washington D.C., District of Columbia
Kerecis Ltd.Not on our public-company list
NCT01348581 · 37 participants · Start Nov 2010 · Primary completion Dec 2012
Device: Marigen Wound Dressing · For: Pressure Ulcers; Venous Ulcers; Diabetic Ulcers and 2 more
Sites: Reykjavik, Iceland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Marigen", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code KGN
154 reports: 32 malfunction, 117 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Marigen"[tiab]. The summary above synthesizes these.
- Human Skeletal Muscle Myoblast Culture in Aligned Bacterial Nanocellulose and Commercial Matrices.
Mastrodimos M, Jain S, Badv M, et al. · ACS Appl Mater Interfaces · 2024Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparative effectiveness of porcine placental extracellular matrix against other cellular, acellular and matrix-like products in diabetic foot ulcers from the Medicare database.
Marcinek B, Levinson J, Nally S, et al. · J Comp Eff Res · 2025Comparative Study, Research Support, Non-U.S. Gov't
- Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances.
Eugster C, Rivara G, Forni G, et al. · Panminerva Med · 1996
- Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study.
Baldursson BT, Kjartansson H, Konrádsdóttir F, et al. · Int J Low Extrem Wounds · 2015
Other devices of this type
Also filed under product code KGN.
- Cytal® Wound MatrixAcell, Inc. · 510(k) 2024
- PriMatrix Dermal Repair ScaffoldTei Biosciences, Inc. · 510(k) 2016
- MatriDermMedskin Solutions Dr. Suwelack AG · 510(k) 2026
- CollOvine Wound PowderOvigenex, LLC · 510(k) 2026
- SurgiAid Collagen Wound Dressing (HA)Maxigen Biotech, Inc. · 510(k) 2025
- Collagen Wound DressingWinner Medical Co., Ltd. · 510(k) 2025
- Corplex P/ Theracor P/ Allacor PStimlabs, LLC · 510(k) 2024
- Foundation Dermal Regeneration Scaffold (DRS) SoloBionova Medical, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.